Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience


Tatar B., Kose S., Ergun N. C. , Turken M., ÖNLEN Y., YILMAZ Y., et al.

REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, cilt.65, ss.1470-1475, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 65 Konu: 12
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1590/1806-9282.65.12.1470
  • Dergi Adı: REVISTA DA ASSOCIACAO MEDICA BRASILEIRA
  • Sayfa Sayısı: ss.1470-1475

Özet

OBJECTIVE: The recent development of direct-acting antiviral agents (DAAs) has dramatically changed the treatment of chronic hepatitis C, and interferon-based regimes have become a poor treatment choice in clinical practice. Today DAAs offer shorter, well-tolerated, highly effective curative therapies. This study aimed to evaluate the effectiveness and safety of DAAs in patients with end-stage renal disease and HCV genotype 1 infection in real clinical practice.